Concepedia

Publication | Open Access

P160 The first phase 2A proof-of-concept study of a selective NLRP3 inflammasome inhibitor, dapansutrile™ (OLT1177™), in acute gout

DOIFull Paper Access

16

Citations

1

References

2019

Year

Viola Klück, M. Janssen, Antoaneta Comarniceanu, M. Efdé, CL Scribner, RB Barrow, DB Skouras, CA Dinarello, L.A.B. Joosten
Annals of the Rheumatic Diseases

References

YearCitations

Page 1